-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 13, 2021, Bellus Health announced that a phase 2b clinical trial of the selective oral P2X3 receptor antagonist BLU-5937 has obtained positive results
P2X3 receptors are ion channels expressed on sensory nerves, and they play an important role in the sensitization of various stimuli in the nervous system
The results of the test showed that on the 28th day, the placebo-adjusted 24-hour cough frequency of the 50 mg and 200 mg BLU-5937 groups was reduced by 34%, which was clinically significant and statistically significant (p≤0.
▲Efficacy results of BLU-5937 (picture source: BELLUS Health official website)
In addition, the safety and tolerability data of BLU-5937 are consistent with previous trials, and have a lower impact on patients' taste.
Reference materials:
[1] BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough.
(The original text has been deleted)